Printer Friendly

PAINEWEBBER INCORPORATED ADDS PET INC. AND GENZYME TO ITS FOCUS LIST

 PAINEWEBBER INCORPORATED ADDS PET INC. AND GENZYME TO ITS FOCUS LIST
 NEW YORK, Dec. 12 /PRNewswire/ -- PaineWebber Incorporated announced today that it has added two companies to its group of stocks known as the PaineWebber Focus List. They are Pet Inc. (NYSE: PT) and Genzyme Corp. (NASDAQ: GENZ). The Focus List is a dynamic, carefully chosen list of select companies that the firm has rated buy or attractive.
 Since inception in 1982, the Focus List was up 611 percent (A) through the end of September 1991 on a total return basis. This performance compares favorably with that of the S&P Index at 371 percent.
 The Focus List uses a method of stock selection designed to maximize growth potential and minimize risk. The 30 stocks that comprise the Focus List are chosen by a committee of senior PaineWebber professionals whose selection criteria combine elements of fundamental, quantitative and technical analysis.
 After a stock is chosen, it is scrutinized daily and is removed from the list when one of two things happens: the PaineWebber analyst downgrades the stock, or the Focus List's proprietary Stop-Loss discipline indicates that the price threshold has been violated.
 Pet, Incorporated, a spinoff from Whitman Corp. in April 1991, is headquartered in St. Louis. They are a prepared specialty foods company whose brand names include Old El Paso Mexican foods, Progresso Italian foods, Accent food flavorings and Whitmans' candy. Company revenues were $1.9 billion in 1990.
 Genzyme Corp., headquartered in Boston, is a biotechnology company whose current premier product, ceradase, treats gaucher's disease. Genzyme also develops other medical products and organic chemicals. Company revenues were $54.8 million in 1990.
 Carolyn J. Cole, senior vice president and chairman of the Focus List Committee, said about the selections, "We believe that both these companies are excellent additions to the Focus List. Pet Inc. fits our strategy of finding companies that we believe will exhibit superior earnings growth in the sluggish economic environment. Health care industry stocks should be included in all growth portfolios."
 Roger Spencer, PaineWebber's food analyst, said about Pet, "Pet's earnings growth over the next three years is projected to be the highest among the major packaged food companies."
 Linda Miller, PaineWebber's biotechnology analyst, said about Genzyme, "Because of the strong product pipeline in development across the biotechnology sector, we continue to recommend select investments in the field. Genzyme is one of the well-capitalized companies we recommend."
 To receive recent performance data or a complete list of stocks on the Focus List and additional information about those stocks, please contact any investment executive at your nearest PaineWebber office.
 PaineWebber Incorporated is one of the nation's leading full-service securities firms with 270 offices and 4,500 investment executive worldwide.
 (A) Total return is a measure of capital appreciation plus dividends for the period from 4/16/82 through 6/30/91, excluding commissions. Adjustments for commissions would significantly reduce total return. Of course, past performance in no indicator of future results. Complete records of all transactions and details of methodology are available upon request.
 -0- 12/12/91
 /CONTACT: Beverly T. Spano of PaineWebber Incorporated, 201-902-6775, or Jeffrey Z. Taufield of Kekst & Company, 212-593-2655/
 (PT GENZ) CO: PaineWebber Incorporated; Pet Inc.; Genzyme Corp. ST: Missouri, Massachusetts IN: FIN SU:


SM-KW -- NY086 -- 2129 12/12/91 16:51 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 12, 1991
Words:552
Previous Article:MICHIGAN BOATING INDUSTRIES ASSOCIATION DIRECTORS ELECTED AT ANNUAL CONFERENCE
Next Article:NEWBRIDGE AND DYNATECH ANNOUNCE SUCCESSFUL FRAME RELAY INTEROPERABILITY TESTING
Topics:


Related Articles
PAINEWEBBER ADDS BAKER HUGHES AND WASTE MANAGEMENT TO ITS FOCUS LIST
PAINEWEBBER INCORPORATED ADDS TENNECO AND KAUFMAN AND BROAD HOME TO ITS FOCUS LIST
PAINEWEBBER ADDS GENERAL MILLS AND GENZYME TO ITS FOCUS LIST
PAINEWEBBER INCORPORATED ADDS BIOMET, INC. TO ITS FOCUS LIST
UNDERWRITERS FOR GENZYME GENERAL DIVISION STOCK OFFERING PURCHASE ADDITIONAL SHARES
GENZYME TRANSGENICS OFFERING 3 MILLION SHARES
GENZYME TRANSGENICS ANNOUNCES PUBLIC OFFERING OF 3,000,000 SHARES AT $4.00 PER SHARE
Genzyme General, ACADIA Pharmaceuticals Collaborate in Search for New Drugs Using Cell-Based Screening Technology
Genzyme Corp. Reports ISS Recommends Formation of Genzyme Biosurgery.
Pacira Pharmaceuticals, Inc. Adds Experienced CFO James S. Scibetta to Leadership of the Organization.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters